The full phase 3 data from the INTerpath-001 trial were published this week, and what they show is at once confirmation that mRNA technology has finally reached maturity — and a cautionary tale about how biology doesn't simply yield because phase 2 numbers were promising.
The partnership between Moderna and Merck, launched in 2016, has culminated in a personalized vaccine called intismeran autogene (also known as mRNA-4157 or V940), designed not to prevent melanoma but to stop it from returning after surgical tumor removal. The design is elegant: the patient's tumor genome is sequenced, unique mutations (neoantigens) are identified, and a personalized vaccine is manufactured that instructs the immune system to recognize and attack cancer cells based precisely on that mutational signature.
The vaccine is administered in combination with Keytruda (pembrolizumab), Merck's PD-1 checkpoint inhibitor, which is already a standard-of-care for metastatic and adjuvant melanoma. The collaboration's hypothesis was that the vaccine would create a tumor-directed immune response while Keytruda removed the brakes on the immune system, enabling vaccine-primed T cells to attack with greater force.
The phase 3 results, presented last week at the ESMO Congress in Madrid, were published hastily after data were leaked online. The presentation was scheduled for Saturday, October 24, but the leak forced Merck and Moderna to publish the numbers on Thursday, October 22.
The primary numbers are clear. Recurrence-free survival (RFS) at 24 months was 82.2% in the intismeran + Keytruda group versus 70.0% in the Keytruda-only control group. The hazard ratio was 0.58, meaning that adding the personalized vaccine reduced the risk of recurrence or death by 42%. In practical terms, that translates to roughly 12 percentage points of absolute difference — and in a study of 1,137 patients, that is statistically robust and clinically meaningful.
What analysts found interesting is that the HR of 0.58 landed near the lower end of what experts had predicted — some had forecast a range between 0.5 and 0.8. One oncologist cited by TD Cowen noted that "commercial enthusiasm will rest on the totality of evidence" — and not the isolated number alone. An HR of 0.58 is not the "moonshot" 0.5 that some investors hoped for, but it sits comfortably within the range considered clinically meaningful by the FDA for accelerated approval.
Here is the detail that investors and analysts are weighing with caution: distant metastasis-free survival (DMFS) data were weaker than expected based on phase 2 results. In phase 2b, the distant metastasis risk reduction was 65%; in the 5-year phase 2 analysis, it was 59%. In phase 3, it dropped to 38% (HR 0.62; 88.5% vs 80.2%). DMFS is often considered the "more interesting" endpoint than RFS because it relates directly to mortality — and Moderna executives have consistently highlighted DMFS as one of the particularly meaningful endpoints.
The most plausible explanation for the difference between phases may lie in the patient population. The KEYNOTE-942 phase 2b trial had only 157 patients, while the INTerpath-001 phase 3 trial had 1,137 — six times more patients, which is statistically much more powerful, but which also tends to reveal more modest effects than the signals observed in small cohorts. This phenomenon has been observed in other areas of oncology: what looks promising in a small phase 2 does not always translate into equivalent magnitude in a phase 3.
Treatment safety deserves attention. Treatment-related adverse events occurred in 95.8% of patients in the combination group versus 90% in the Keytruda-alone control group. Grade 3 to 5 events were 14.2% versus 13.4%. No new safety signals emerged — meaning the safety profile of the combination is basically Keytruda's with a modest addition, not a dramatic shift.
What no one was asking, but what is crucial: overall survival (OS) remains immature. This is not surprising — OS is the most difficult endpoint to show in adjuvant melanoma, because the disease recurs in such varied forms and the follow-up time required is long. Researchers note that longer follow-up is needed to establish whether patients receiving the combination live longer. Until then, the surrogate endpoints (RFS and DMFS) are what support the case for approval.
The financial history is revealing. When preliminary results were announced in August, Moderna's shares surged 170% in a single trading day. After the leak and full data publication last week, Moderna's shares fell sharply — and Merck also retreated, albeit more modestly. One financial analyst cited by Forbes observed that this likely reflects "inflated expectations for the full data release, rather than a true indictment of the combination therapy."
What the intismeran program represents, in historical perspective, is the culmination of a decade's bet on immunotherapy combined with precision biology. Since 2016, Merck and Moderna have built a development partnership that has already yielded more than a dozen clinical trials across multiple cancer types — the INTerpath program encompasses nine phase 2 and phase 3 studies in melanoma, lung cancer, gastric cancer, and ductal adenocarcinoma. Melanoma was only the first indication, but approval here would open the path for indications in other tumors where personalized vaccination might offer the same type of advantage.
The logistics of personalized production is the challenge no one discusses publicly. Each intismeran vaccine is manufactured to the mutational profile of a single patient — which means tumor sequencing, bioinformatic analysis, mRNA synthesis, and administration within precise time windows. Under the current model, this happens after surgical tumor removal, at a moment when the patient is clinically stable. Manufacturing takes weeks, not days. Translating this model to global scale — with potentially hundreds of thousands of eligible patients — requires a supply chain that does not yet exist.
The FDA has a pathway for personalized melanoma vaccine approval. The breakthrough therapy designation has already been granted to intismeran, which means accelerated follow-up and priority review. If the FDA approves intismeran, it will be the first therapeutic cancer vaccine approved in the United States — and the most significant milestone since the discovery of checkpoint inhibitors, more than a decade ago.
The question that remains: if melanoma is the first cancer to be conquered by a personalized vaccine, what other tumors are prepared to follow the same path? The INTerpath program is already testing intismeran in NSCLC, gastric cancer, and ductal adenocarcinoma. If the biological mechanism — immunizing the patient against their own tumor mutations — works in other cancer types, the "personalized vaccine" model could become the new standard for adjuvant treatment of virtually every tumor that can be sequenced. The melanoma phase 3 was the moment precision biology came of age. What happens next depends on how long the industry is willing to invest to make personalized medicine at scale a reality.
Sources: STAT, Nature, The Sydney Morning Herald
✓ Independent sources cross-checked and verified before publishing
